Segment Information - Schedule of Revenue and Adjusted EBITDA by Segment (Details) - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Segment Revenue
Total revenue	$ 40,414,000	$ 60,864,000
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(35,162,000)	(49,800,000)
Net loss	(69,400,000)	(104,624,000)
Adjustments:
Interest income, net	(2,574,000)	(4,307,000)
Other (income) expense, net	19,000	(333,000)
Depreciation and amortization	4,011,000	4,478,000
Amortization of acquired intangible assets	1,776,000	3,638,000
Stock-based compensation expense	21,577,000	51,100,000
Transaction costs related to disposition of Lemonaid Health	0	248,000
Cyber security incident expenses, net of probable insurance recoveries	9,429,000	0
Total Adjusted EBITDA	(35,162,000)	(49,800,000)
Corporate, Non-Segment
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(13,904,000)	(13,060,000)
Consumer and Research Services
Segment Revenue
Total revenue	40,414,000	60,864,000
Consumer and Research Services | Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(8,841,000)	(5,602,000)
Therapeutics
Segment Revenue
Total revenue	0	0
Therapeutics | Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	$ (12,417,000)	$ (31,138,000)